Enliven Therapeutics (ELVN) Competitors $22.66 -0.68 (-2.91%) Closing price 04:00 PM EasternExtended Trading$22.68 +0.02 (+0.09%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELVN vs. ZLAB, PTCT, RARE, AAPG, MRUS, ACLX, SWTX, RNA, ACAD, and SRRKShould you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include Zai Lab (ZLAB), PTC Therapeutics (PTCT), Ultragenyx Pharmaceutical (RARE), Ascentage Pharma Group International (AAPG), Merus (MRUS), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), Avidity Biosciences (RNA), ACADIA Pharmaceuticals (ACAD), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry. Enliven Therapeutics vs. Its Competitors Zai Lab PTC Therapeutics Ultragenyx Pharmaceutical Ascentage Pharma Group International Merus Arcellx SpringWorks Therapeutics Avidity Biosciences ACADIA Pharmaceuticals Scholar Rock Zai Lab (NASDAQ:ZLAB) and Enliven Therapeutics (NASDAQ:ELVN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership. Is ZLAB or ELVN more profitable? Enliven Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -60.26%. Enliven Therapeutics' return on equity of -31.84% beat Zai Lab's return on equity.Company Net Margins Return on Equity Return on Assets Zai Lab-60.26% -33.35% -23.28% Enliven Therapeutics N/A -31.84%-30.09% Do analysts rate ZLAB or ELVN? Zai Lab presently has a consensus price target of $54.28, suggesting a potential upside of 61.68%. Enliven Therapeutics has a consensus price target of $41.20, suggesting a potential upside of 81.82%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Enliven Therapeutics is more favorable than Zai Lab.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zai Lab 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, ZLAB or ELVN? Zai Lab has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Does the media refer more to ZLAB or ELVN? In the previous week, Enliven Therapeutics had 3 more articles in the media than Zai Lab. MarketBeat recorded 7 mentions for Enliven Therapeutics and 4 mentions for Zai Lab. Zai Lab's average media sentiment score of 1.19 beat Enliven Therapeutics' score of 0.71 indicating that Zai Lab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of ZLAB or ELVN? 41.7% of Zai Lab shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 5.0% of Zai Lab shares are held by company insiders. Comparatively, 25.9% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger valuation & earnings, ZLAB or ELVN? Enliven Therapeutics has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZai Lab$398.99M9.35-$257.10M-$2.49-13.48Enliven TherapeuticsN/AN/A-$89.02M-$1.92-11.80 SummaryEnliven Therapeutics beats Zai Lab on 10 of the 14 factors compared between the two stocks. Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELVN vs. The Competition Export to ExcelMetricEnliven TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.15B$2.46B$5.54B$9.41BDividend YieldN/A1.80%3.75%4.03%P/E RatioN/A4.4521.0120.09Price / SalesN/A709.89433.8199.01Price / CashN/A164.7736.1658.27Price / Book3.575.008.125.65Net Income-$89.02M$30.99M$3.25B$257.91M7 Day Performance0.94%1.69%0.97%2.09%1 Month Performance5.05%9.20%7.36%11.13%1 Year Performance0.27%-1.25%31.31%18.40% Enliven Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELVNEnliven Therapeutics2.8636 of 5 stars$22.66-2.9%$41.20+81.8%-1.8%$1.15BN/A0.0050News CoverageZLABZai Lab3.3179 of 5 stars$35.48-2.5%$54.28+53.0%+92.2%$4.04B$398.99M-14.251,869PTCTPTC Therapeutics4.4456 of 5 stars$47.98-2.2%$65.00+35.5%+41.9%$3.89B$806.78M7.371,410News CoverageInsider TradeAnalyst RevisionRAREUltragenyx Pharmaceutical4.3814 of 5 stars$39.61-0.8%$87.00+119.6%-37.5%$3.77B$560.23M-6.741,294Trending NewsAnalyst RevisionGap DownAAPGAscentage Pharma Group InternationalN/A$42.04-1.9%N/AN/A$3.73B$134.35M0.00600Lockup ExpirationMRUSMerus1.9328 of 5 stars$52.58-2.3%$84.64+61.0%+8.6%$3.73B$36.13M-12.8937News CoverageInsider TradeACLXArcellx2.5337 of 5 stars$65.55-2.4%$111.23+69.7%+8.3%$3.70B$107.94M-21.9280Positive NewsSWTXSpringWorks Therapeutics1.3584 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230News CoverageRNAAvidity Biosciences2.1866 of 5 stars$28.80-1.3%$65.59+127.7%-24.6%$3.52B$10.90M-9.60190ACADACADIA Pharmaceuticals3.9879 of 5 stars$20.88-0.3%$27.88+33.5%+22.9%$3.51B$957.80M15.24510SRRKScholar Rock3.1299 of 5 stars$35.48-1.4%$42.67+20.3%+378.9%$3.42B$33.19M-14.02140Analyst ForecastInsider Trade Related Companies and Tools Related Companies Zai Lab Competitors PTC Therapeutics Competitors Ultragenyx Pharmaceutical Competitors Ascentage Pharma Group International Competitors Merus Competitors Arcellx Competitors SpringWorks Therapeutics Competitors Avidity Biosciences Competitors ACADIA Pharmaceuticals Competitors Scholar Rock Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELVN) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELVN Stock Alerts